Peptide cycling claims on TikTok: which peptides need breaks and why NAD+ may not

A recent TikTok video by nurse practitioner MJ Gandon warns viewers that certain peptides should not be used continuously. The clip suggests that some compounds require cycling to prevent side effects like water retention, while NAD+ is presented as safe and powerful for daily use to support cellular health and longevity. The underlying message is that guessing your protocol is suboptimal and that clinical customization is necessary.

What the clip is claiming

The video makes two broad claims. First, that some peptides—likely referring to growth hormone secretagogues such as tesamorelin and sermorelin—need to be cycled to avoid issues like water retention. Second, that NAD+ is uniquely suited for continuous use without such concerns. The clip implies that a one-size-fits-all approach is risky and that professional guidance is essential.

What the research neighborhood actually covers

Peptide cycling is a common practice in research and clinical settings, but the evidence base is nuanced. For growth hormone-releasing peptides and hormones, intermittent protocols are often used to maintain responsiveness and minimize desensitization. Tesamorelin, a synthetic GHRH analog, has been studied in daily dosing for HIV-associated lipodystrophy, but long-term continuous use is not universally recommended. Sermorelin, another GHRH analog, is frequently administered in cycles, though data on optimal cycling schedules are limited.

Water retention is a known side effect of growth hormone secretagogues, partly due to their effect on fluid balance. However, the degree and clinical significance vary by compound and individual. For NAD+ precursors, the research focuses on cellular energy metabolism and sirtuin activation, with no established need for cycling in animal models or early human studies. Continuous supplementation is common in longevity protocols, but long-term safety data are still emerging.

Limits, missing context, and what a 15-second clip cannot show

A short video cannot convey the complexity of peptide protocols. It omits dosing, duration, and individual variability. It also fails to distinguish between different classes of peptides—GHRH analogs, GHRP-6, and NAD+ have distinct mechanisms and side effect profiles. The claim that NAD+ is safe for continuous use is based on preliminary research, not long-term human trials. Similarly, the assertion that cycling prevents water retention is not universally supported by peer-reviewed studies; some peptides cause water retention regardless of schedule.

Moreover, the clip does not address contraindications, drug interactions, or the importance of monitoring biomarkers. It also implies that clinical customization is always superior, but in a research context, protocols are experimental and should be guided by a qualified professional.

How this maps to named research compounds

The clip explicitly mentions tesamorelin and sermorelin, both of which are in our catalog. Tesamorelin is a GHRH analog studied for its effects on visceral fat and metabolic health. Sermorelin is another GHRH analog used in research to stimulate endogenous GH release. For these compounds, cycling is often considered to preserve pituitary responsiveness, but evidence is mixed. NAD+ is also in our catalog; it is a coenzyme involved in redox reactions and is being studied for its role in aging and cellular repair. Continuous NAD+ supplementation is common in research protocols, but the optimal regimen remains under investigation.

Other catalog compounds, such as Ipamorelin and CJC-1295, are also growth hormone secretagogues that may require cycling, but the clip does not mention them. We limit our analysis to the compounds named in the video.

Research-use caveat

All peptides listed are for research use only and are not approved for human consumption or clinical use. This article is for educational purposes and does not constitute medical advice. Researchers should consult primary literature and follow institutional guidelines when designing protocols.